Acumen Pharmaceuticals (ABOS) vs Blue Water Acquisition III - Unit. (BLUWU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Blue Water Acquisition III - Unit. (BLUWU) over the past year, gaining 11.7% versus a gain of 4.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | BLUWU |
|---|---|---|
| Share price | $2.10 | $10.50 |
| Market cap | $151.87M | — |
| 1-day change | 0.00% | 0.00% |
| YTD return | -0.47% | -0.47% |
| 1-year return | +11.70% | +4.69% |
| 5-year return | -84.50% | — |
| EPS (TTM) | $-1.64 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $12.85 |
| 52-week low | $1.50 | $10.03 |
| Distance from 52-week high | -41.67% | -18.29% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +261.90% | — |
| Average volume | 439.10K | 48 |
| Shares outstanding | 72.32M | — |
| Employees | 60 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
ABOS vs BLUWU FAQ
Which stock has performed better over the past year, ABOS or BLUWU?
ABOS returned +11.70% over the past 12 months, compared with +4.69% for BLUWU (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Blue Water Acquisition III - Unit. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.